Immunotherapy provides long-term survival benefits for more patients with esophageal cancer.

China's annual new esophageal cancer about 246,000 cases, 188,000 deaths, in order to promote China's esophageal cancer field authoritative experts and multidisciplinary doctors to cooperate and exchange, leading China's comprehensive diagnosis and treatment of esophageal cancer into a new stage, by The Beijing University Cancer Hospital Vice President, Beijing Cancer Prevention and Control Society rotating chairman Professor Shen Lin as the chairman of the "Beijing Cancer Prevention and Control Society Esophageal Cancer Professional Committee", officially established in Beijing on September 6. The members of the
adm committee come from more than 70 hospitals in China, including Peking University Oncology Hospital, Oncology Hospital of the Chinese Academy of Medical Sciences, and Hebei Medical University Fourth Hospital, covering clinicians and scholars engaged in basic medical research in the fields of internal medicine, surgery, radiotherapy, imaging and pathology.
Shen Lin, China's esophageal cancer incidence and death accounted for more than half of the world, china's middle and late esophageal cancer patients five-year survival rate of less than 20%.
The reason is partly due to the early symptoms of esophageal cancer hidden, screening is difficult, resulting in 70% of esophageal cancer patients diagnosed with late middle and late stage, treatment is difficult, treatment methods are limited and patients with poor prognostic, especially late patients due to high tumor load often have lost the opportunity for curative surgery.
on the other hand, because of China's esophageal cancer in the affected population, high-risk factors and pathological types, there are significant differences in Western countries, the Western esophageal adenocarcinoma is high, and more than 90% of patients in China are esophageal squamous cancer.
Professor Shen Lin said that compared with other types of cancer, there has been no breakthrough in treatment and survival improvement of esophageal cancer for decades, and that in recent years the success of immunotherapy in the treatment of esophageal cancer has broken through this "bottleneck", immunotherapy combined chemotherapy or other therapies will provide long-term survival benefits for more patients with esophageal cancer.
studies showed that the median total survival time of immunotherapy Pabliju single-dose contrast chemotherapy treatment PD-L1 expression-positive esophageal squamous cancer patients increased from 5.4 months to 12 months, the risk of death decreased by 62%, to more than one year of survival patients are three times the chemotherapy group, the efficacy, long-term survival benefits and safety are significantly better than traditional standard treatment and Chinese groups benefit better.
2019, the world's first immunotherapy drug for esophageal cancer, Paboli juju monoantigen, was approved in the United States, and in June 2020 Paboli juju monoantigen was approved in China for the treatment of patients with second-line advanced esophageal squamous cancer.
"Immune therapy has allowed us to see the dawn of treatment of esophageal squamous cancer, and the success of Paboli Pearl monoimmune therapy in the second-line treatment of esophageal cancer is encouraging, and if it is used in the first-line treatment or even earlier in the future, there may be more patients with esophageal cancer benefiting from it, " said Dr. Yin Qingxia, consultant to the adjournment committee and director of oncology at Zhengzhou University's First Affiliated Hospital.
S. Shen Lin said: "Because the immune environment is more immune for patients with primary treatment for esophageal cancer, we look forward to a better outcome for Pabliju monoantigen in the first line."
At the upcoming annual meeting of the European Society of Oncology (ESMO), the positive results of The positive results of The test results of The first-line treatment of esophageal cancer will be announced, which will be the world's first clinical trial of PD-1 inhibitor combination chemotherapy comparing chemotherapy options in first-line esophageal cancer treatment, and as one of the lead researchers, I believe the results of the upcoming first-line treatment are expected to rewrite the pattern of treatment of esophageal cancer.
" ()